Advertisement

Pharmacological Tools in Endocannabinoid Neurobiology

  • Marco MorEmail author
  • Alessio Lodola
Chapter
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 1)

Abstract

Pharmacological and biochemical investigations on the endocannabinoid system are facilitated by the availability of compounds which interact with its constituents in specific and understandable ways. This chapter describes the main representatives of several classes of chemicals employed as pharmacological tools in this field, focusing on small organic compounds having, where possible, a drug-like structure. Many compounds having different intrinsic activity and selectivity towards the G-protein coupled receptors (GPCR) CB1 and CB2 are now available and are currently employed in research protocols. Recently, allosteric ligands for CB1 receptor and selective ligands for GPR55, a newly characterised GPCR, have also been described in the literature. As for compounds affecting endocannabinoid levels in living tissues, many classes of selective and, in some cases, drug-like inhibitors of FAAH are available, while only compounds with poor selectivity or in vivo activity are known to inhibit other enzymes involved in endocannabinoid catabolism, such as NAAA or MGL, and in endocannabinoid biosynthesis.

Keywords

CB1 ligands CB2 ligands Anandamide Transport FAAH inhibitors MGL inhibitors NAAA inhibitors 

Abbreviations

2-AG

2-Arachidonoylglycerol

AEA

Anandamide

CCP

N-(cyclohexylcarbonyl)pentadecylamine

DAG

Diacylglycerol

ECB

Endocannabinoid

FAAH

Fatty acid amide hydrolase

GPCR

G protein-coupled receptor

MGL

Monoacylglycerol lipase

NAAA

N-Acylethanolamine acid amidase

NAE

N-Acylethanolamine

NAPE-PLD

N-Acylphosphatidylethanolamine phospholipase D

OEA

N-Oleoylethanolamine

PA

Phosphatidic acid

PEA

N-Palmitoylethanolamine

PLC

Phospholipase C

TRPV1

Transient receptor potential vanilloid type 1

Δ9-THC

Δ9-Tetrahydrocannabinol

References

  1. Ahn K, Johnson DS, Fitzgerald LR et al. (2007) Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 46:13019–13030PubMedGoogle Scholar
  2. Alexander JP, Cravatt BF (2005) Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol 12:1179–1187PubMedGoogle Scholar
  3. Bari M, Battista N, Fezza F et al. (2006) New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6:257–268PubMedGoogle Scholar
  4. Bayewitch M, Rhee M-H, Avidor-Reiss T et al. (1996) (-)-Δ9-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 27:19902–19905Google Scholar
  5. Beltramo M, Stella N, Calignano A et al. (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094–1097PubMedGoogle Scholar
  6. Bingham B, Jones PG, Uveges AJ et al. (2007) Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 151:1061–1070PubMedGoogle Scholar
  7. Bisogno T, Howell F, Williams G et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163:463–468PubMedGoogle Scholar
  8. Bisogno T, Cascio MG, Saha B et al. (2006) Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761:205–212PubMedGoogle Scholar
  9. Boger DL, Sato H, Lerner AE et al. (2000) Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 97:5044–5049PubMedGoogle Scholar
  10. Boger DL, Miyauchi H, Du W et al. (2005) Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 48:1849–1856PubMedGoogle Scholar
  11. Bortolato M, Mangieri RA, Fu J et al. (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62:1103–1110PubMedGoogle Scholar
  12. Brown AJ (2007) Novel cannabinoid receptors. Br J Pharmacol 152:567–575PubMedGoogle Scholar
  13. De Petrocellis L, Melck D, Ueda N et al. (1997) Novel inhibitors of brain neuronal and basophilic anandamide amidohydrolase. Biochem Biophys Res Commun 231:82–88PubMedGoogle Scholar
  14. Deutsch DG, Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791–796PubMedGoogle Scholar
  15. Deutsch DG, Lin S, Hill WA et al. (1997) Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun 3:217–221Google Scholar
  16. Devane WA, Dysarz FA III, Johnson MR et al. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605–613PubMedGoogle Scholar
  17. Di Marzo V, De Petrocellis L, Sepe N et al. (1996) Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 316:977–984PubMedGoogle Scholar
  18. Di Marzo V, Bisogno T, De Petrocellis L et al. (1999) Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264:258–267PubMedGoogle Scholar
  19. Di Marzo V, Bisogno T, De Petrocellis L et al. (2001) Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor “hybrid” ligands. Biochem Biophys Res Commun 281:444–451PubMedGoogle Scholar
  20. Dinh TP, Carpenter D, Leslie FM et al. (2002a) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819–10824PubMedGoogle Scholar
  21. Dinh TP, Freund TF, Piomelli D (2002b) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 31:149–158Google Scholar
  22. Elsohly MA (2002) Chemical constituents of cannabis. In: Grotenherman F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology and therapeutic potential. Haworth Press, Binghamton, NYGoogle Scholar
  23. Ermann M, Riether D, Walker ER et al. (2008) Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity. Bioorg Med Chem Lett 18:1725–1729PubMedGoogle Scholar
  24. Fegley D, Kathuria S, Mercier R et al. (2004) Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA 101:8756–8761PubMedGoogle Scholar
  25. Felder CC, Joyce KE, Briley EM et al. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443–450PubMedGoogle Scholar
  26. Fong TM, Guan XM, Marsh DJ et al. (2007) Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S, 2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl) pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 321:1013–1022PubMedGoogle Scholar
  27. Fowler CJ, Tiger G, Ligresti A et al. (2004) Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis: a difficult issue to handle. Eur J Pharmacol 492:1–11PubMedGoogle Scholar
  28. Fowler CJ, Holt S, Nilsson O et al. (2005) The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav 81:248–262PubMedGoogle Scholar
  29. Fu J, Gaetani S, Oveisi F et al. (2003) Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425:90–93PubMedGoogle Scholar
  30. Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646–1647Google Scholar
  31. Gardner A, Mallet PE (2006) Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor ‘silent antagonist’. Eur J Pharmacol 530:103–106PubMedGoogle Scholar
  32. Gertsch J, Raduner S, Altmann KH (2006) New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors. J Recept Signal Transduct Res 26:709–730PubMedGoogle Scholar
  33. Ghafouri N, Tiger G, Razdan RK et al. (2004) Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br J Pharmacol 143:774–784PubMedGoogle Scholar
  34. Giblin GM, O’Shaughnessy CT, Naylor A et al. (2007) Discovery of 2-[(2, 4-dichlorophenyl) amino]-N-[(tetrahydro-2H-pyran-4-yl) methyl]-4-trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem 50:2597–2600PubMedGoogle Scholar
  35. Glaser S, Abumrad N, Fatade F et al. (2003) Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 100:4269–4274PubMedGoogle Scholar
  36. Gobbi G, Bambico FR, Mangieri et al. (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102:18620–18625Google Scholar
  37. Gonsiorek W, Hesk D, Chen SC et al. (2006) Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336. J Biol Chem 281:28143–28151PubMedGoogle Scholar
  38. Gonsiorek W, Lunn CA, Fan X et al. (2007) Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates. Br J Pharmacol 151:1262–1271PubMedGoogle Scholar
  39. Gonsorek W, Lunn C, Fan X et al. (2000) Endocannabinoid 2-AG is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 57:1045–1050Google Scholar
  40. Guindon J, Hohmann AG (2008) Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153:319–334PubMedGoogle Scholar
  41. Guindon J, Desroches J, Beaulieu P (2007) The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 150:693–701PubMedGoogle Scholar
  42. Hanus L, Breuer A, Tchilibon S et al. (1999) HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96:14228–14233PubMedGoogle Scholar
  43. Hillard CJ, Manna S, Greenberg MJ et al. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289:1427–1433PubMedGoogle Scholar
  44. Hillard CJ, Shi L, Tuniki VR et al. (2007) Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase. J Mol Neurosci 33:18–24PubMedGoogle Scholar
  45. Ho W-SV, Hillard CJ (2005) Modulators of endocannabinoid enzymic hydrolysis and membrane transport. In: Pertwee RG (ed) Cannabinoids. Handbook of experimental pharmacology. Springer, HeidelbergGoogle Scholar
  46. Hohmann AG, Suplita RL, Bolton NM et al. (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108–1112PubMedGoogle Scholar
  47. Horswill JG, Bali U, Shaaban S et al. (2007) PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 152:805–814PubMedGoogle Scholar
  48. Howlett AC, Barth F, Bonner TI et al. (2002) International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161–202PubMedGoogle Scholar
  49. Huffman JW, Liddle J, Yu S et al. (1999) 3-(10, 10-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7:2905–2914PubMedGoogle Scholar
  50. Iwamura H, Suzuki H, Ueda Y et al. (2001) In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 296:420–425PubMedGoogle Scholar
  51. Jagerovic N, Fernandez-Fernandez C, Goya P (2008) CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications. Curr Top Med Chem 8:205–230PubMedGoogle Scholar
  52. Jarrahian A, Manna S, Edgemond WS et al. (2000) Structure–activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J Neurochem 74:2597–2606PubMedGoogle Scholar
  53. Jayamanne A, Greenwood R, Mitchell VA et al. (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147:281–288PubMedGoogle Scholar
  54. Jonsson KO, Persson E, Fowler CJ (2006) The cannabinoid CB2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of β-hexosaminidase from skin slices in vitro. Life Sci 78:598–606PubMedGoogle Scholar
  55. Karlsson M, Contreras JA, Hellman U et al. (1997) cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 272:27218–27223PubMedGoogle Scholar
  56. Kathuria S, Gaetani S, Fegley et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76–81Google Scholar
  57. Khanolkar AD, Lu D, Ibrahim M et al. (2007) Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem 50:6493–6500PubMedGoogle Scholar
  58. Kikuchi A, Ohashi K, Sugie Y et al. (2008) Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J Pharmacol Sci 106:219–224PubMedGoogle Scholar
  59. King AR, Duranti A, Tontini A et al. (2007) URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol 14:1357–1365PubMedGoogle Scholar
  60. Koutek B, Prestwich GD, Howlett AC et al. (1994) Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem 269:22937–22940PubMedGoogle Scholar
  61. Kuster JE, Stevenson JI, Ward SJ et al. (1993) Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther 264:1352–1363PubMedGoogle Scholar
  62. Labar G, Michaux C (2007) Fatty acid amide hydrolase: from characterization to therapeutics. Chem Biodivers 4:1882–1902PubMedGoogle Scholar
  63. Labar G, Bauvois C, Muccioli GG et al. (2007) Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling. Chembiochem 23:1293–1297Google Scholar
  64. Lambert D, Fowler CJ (2005) The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 48:1–29Google Scholar
  65. Lichtman AH, Leung D, Shelton C et al. (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441–448PubMedGoogle Scholar
  66. Lo Verme J, Fu J, Astarita G et al. (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15–19PubMedGoogle Scholar
  67. Lodola A, Mor M, Hermann JC et al. (2005) QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation. Chem Commun (Camb) 35:4399–4401Google Scholar
  68. Lodola A, Mor M, Rivara S et al. (2008) Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. Chem Commun (Camb) 2:214–216Google Scholar
  69. Lopez-Rodrıguez ML, Viso A, Ortega-Gutierrez S et al. (2003) Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J Med Chem 46:1512–1522PubMedGoogle Scholar
  70. Lunn CA, Fine JS, Rojas-Triana A et al. (2006) A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 316:780–788PubMedGoogle Scholar
  71. Maekawa T, Nojima H, Kuraishi Y et al. (2006) The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol 542:179–183PubMedGoogle Scholar
  72. Maione S, De Petrocellis L, de Novellis V et al. (2007) Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150:766–781PubMedGoogle Scholar
  73. Makara JK, Mor M, Fegley D et al. (2005) Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8:1139–1141PubMedGoogle Scholar
  74. Makara JK, Mor M, Fegley D et al. (2007) Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 10:134Google Scholar
  75. Manera C, Benetti V, Castelli MP et al. (2006) Design, synthesis, and biological evaluation of new 1, 8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J Med Chem 49:5947–5957PubMedGoogle Scholar
  76. Martin BR, Wiley JL, Beletskaya I et al. (2006) Pharmacological characterization of novel water-soluble cannabinoids. J Pharmacol Exp Ther 318:1230–1239PubMedGoogle Scholar
  77. McKinney MK, Cravat BF (2005) Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74:411–432PubMedGoogle Scholar
  78. Mechoulam R (2005) Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol 146:913–915PubMedGoogle Scholar
  79. Mechoulam R, Peters M, Murillo-Rodriguez E et al. (2007) Cannabidiol-recent advances. Chem Biodivers 4:1678–1692PubMedGoogle Scholar
  80. Mor M, Rivara S, Lodola A et al. (2004) Cyclohexylcarbamic acid 3’- or 4’-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modelling studies. J Med Chem 47:4998–5008PubMedGoogle Scholar
  81. Muccioli GG (2007) Blocking the cannabinoid receptors: drug candidates and therapeutic promises. Chem Biodivers 4:1805–1827PubMedGoogle Scholar
  82. Muccioli GG, Xu C, Odah E et al. (2007) Identification of a novel endocannabinoid-hydrolysing enzyme expressed by microglial cells. J Neurosci 27:2883–2889PubMedGoogle Scholar
  83. Murineddu G, Lazzari P, Ruiu S et al. (2006) Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3 carboxamide. J Med Chem 49:7502–7512PubMedGoogle Scholar
  84. Ohta H, Ishizaka T, Tatsuzuki M et al. (2008) Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. Bioorg Med Chem 16:1111–1124PubMedGoogle Scholar
  85. Okamoto Y, Wang J, Morishita J et al. (2007) Biosynthetic pathways of the endocannabinoid anandamide. Chem Biodivers 4:1842–1857PubMedGoogle Scholar
  86. Ortar G, Ligresti A, De Petrocellis L et al. (2003) Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 65:1473–1481PubMedGoogle Scholar
  87. Pacher P, Batkay S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:390–462Google Scholar
  88. Pavon FJ, Bilbao A, Hernández-Folgado L et al. (2006) Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-LH 21. Neuropharmacology 51:358–366PubMedGoogle Scholar
  89. Pertwee RG (2005a) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307–1324PubMedGoogle Scholar
  90. Pertwee RG (2005b) Pharmacological action of cannabinoid. In: Pertwee RG (ed) Cannabinoids. Handbook of experimental pharmacology. Springer, HeidelbergGoogle Scholar
  91. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873–884PubMedGoogle Scholar
  92. Piomelli D (2005) The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 6:672–679PubMedGoogle Scholar
  93. Piomelli D, Tarzia G, Duranti A et al. (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12:21–38PubMedGoogle Scholar
  94. Poso A, Huffman JW (2008) Targeting the cannabinoid CB2 receptor: modeling and structural determinants of CB2 selective ligands. Br J Pharmacol 153:335–346PubMedGoogle Scholar
  95. Price MR, Baillie GL, Thomas A et al. (2006) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68:1484–1495Google Scholar
  96. Rinaldi-Carmona M, Barth F, Heaulme M et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244PubMedGoogle Scholar
  97. Rinaldi-Carmona M, Barth F, Millan J et al. (1998) SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644–650PubMedGoogle Scholar
  98. Ross RA (2007) Tuning the endocannabinoid system: allosteric modulators of the CB1 receptor. Br J Pharmacol 152:565–566PubMedGoogle Scholar
  99. Ruiu S, Pinna AG, Marchese G et al. (2003) Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 306:363–370PubMedGoogle Scholar
  100. Russo R, Lo Verme J, La Rana G et al. (2007) The fatty-acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neurophatic pain after oral administration. J Pharmacol Exp Ther 322:236–242PubMedGoogle Scholar
  101. Ryberg E, Larsson N, Sjögren S et al. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101PubMedGoogle Scholar
  102. Saario SM, Laitinen JT (2007a) Monoglyceride lipase as an enzyme hydrolyzing 2-arachidonoylglycerol. Chem Biodivers 4:1903–1913PubMedGoogle Scholar
  103. Saario SM, Laitinen JT (2007b) Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic Clin Pharmacol Toxicol 101:287–293PubMedGoogle Scholar
  104. Saario SM, Savinainen JR, Laitinen JT et al. (2004) Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol 67:1381–1387PubMedGoogle Scholar
  105. Saario SM, Salo OM, Nevalainen T et al. (2005) Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem Biol 12:649–656PubMedGoogle Scholar
  106. Sink KS, McLaughlin PJ, Wood JA et al. (2008) The novel cannabinoid CB(1) receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33:946–955PubMedGoogle Scholar
  107. Song ZH, Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212–2. Mol Pharmacol 49:891–896PubMedGoogle Scholar
  108. Sugiura T, Kishimoto S, Oka S et al. (2006) Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 45:405–446PubMedGoogle Scholar
  109. Suplita RL 2nd, Gutierrez T, Fegley D et al. (2006) Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology 50:372–379PubMedGoogle Scholar
  110. Thomas A, Ross RA, Saha B et al. (2004) 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. Eur J Pharmacol 487:213–221PubMedGoogle Scholar
  111. Thomas A, Stevenson LA, Wease KN et al. (2005) Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146:917–926PubMedGoogle Scholar
  112. Thomas B, Zhang Y, Brackeen M et al. (2006) Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs. AAPS J 8:E665–E671PubMedGoogle Scholar
  113. Tonidandel L, Tarzia G, Antonietti F et al. (2006) On the formation of [H3C-S-S-CH3]+* ions from the bis(dimethylthio) mercury molecular ion. Rapid Commun Mass Spectrom 20:3154–3158PubMedGoogle Scholar
  114. Tsuboi K, Hilligsmann C, Vandevoorde S et al. (2004) N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem J 379(Pt 1):99–106PubMedGoogle Scholar
  115. Tsuboi K, Sun YX, Okamoto Y et al. (2005) Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 280:11082–11092PubMedGoogle Scholar
  116. Tsuboi K, Takezaki N, Ueda N (2007) The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers 4:1914–1925PubMedGoogle Scholar
  117. Ueda N, Yamanaka K, Terasawa Y et al. (1999) An acid amidase hydrolyzing anandamide as an endogenous ligand for cannabinoid receptors. FEBS Lett 454:267–270PubMedGoogle Scholar
  118. Ueda N, Yamanaka K, Yamamoto S (2001) Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 276:35552–35557PubMedGoogle Scholar
  119. Valenzano KJ, Tafesse L, Lee G et al. (2005) Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48:658–672PubMedGoogle Scholar
  120. Vandevoorde S (2008) Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr Top Med Chem 8:247–267PubMedGoogle Scholar
  121. Vandevoorde S, Fowler CJ (2005) Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. Br J Pharmacol 145:885–893PubMedGoogle Scholar
  122. Wang J, Okamoto Y, Morishita J et al. (2006) Functional analysis of the purified anandamide-generating phospholipase D as a member of the metallo-beta-lactamase family. J Biol Chem 281:12325–12335PubMedGoogle Scholar
  123. Wei BQ, Mikkelsen TS, McKinney MK et al. (2006) A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 281:36569–36578PubMedGoogle Scholar
  124. Whiteside GT, Lee GP, Valenzano KJ (2007) The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 14:917–936PubMedGoogle Scholar
  125. Woods SC (2007) The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. JAAPA 20(Suppl Endocannabinoid):7–10Google Scholar
  126. Yao BB, Hsieh GC, Frost JM et al. (2008) In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 153:390–401PubMedGoogle Scholar
  127. Zhang D, Saraf A, Kolasa T et al. (2007) Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology 52:1095–1105PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Dipartimento FarmaceuticoUniversità degli Studi di ParmaParmaItaly

Personalised recommendations